igxt
- Creatore Discussione axelvento
- Data di inizio
-
INVESTIMENTO IN LENDING CROWDFUNDING SU WALLIANCE: 21 MESI E CEDOLE TRIMESTRALI
Su Walliance è aperto l’investimento in Lending “Padova, Residence Linea 4.0”. Durata 21 mesi; distribuzione del TAN in cedole trimestrali; restituzione del capitale alla scadenza del finanziamento.
Campagna di raccolta investimenti > 90%.
Ticket minimo € 500.
Per continuare a leggere visita questo LINK
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
igxt zero debito
DD------
THIS UNKNOWN GEM IS THE CHEAPEST STOCK WITH THE HIGHEST UPSIDE POTENTIAL IN THE COMPLETE BIOTECH SECTOR .DO YOUR OWN DD AND REALIZE THE MEGA MONSTER POTENTIAL ! GLTA
This Goldmine has a VERY LOW burn-rate of only $1.2 M a year means we have enuff cash untill 2014 EXCLUDING cpi-300 revenue and EXCLUDING upfront payments from upcoming partnerships BUT MORE IMPORTANT TO KNOW IS THAT WE WILL REACH PROFITABILITY THIS YEAR !!!
2x NDA filings for Migraine and Antipsychotic drugs this year which have much bigger market potential than current approved drug .
IGXT has NO DEBT and the Market cap of only 32 M is more than RIDICULOUS for this GOLDMINE .
Intelgenx (IGXT.OB)
Market Cap : $ 32 M
Cash: $ 3.3 M
Price : 0.68 $
NO DEBT
Shares Out : 45 M ( 23 M shares are held by Insiders + Institutions)
HEAVY BUYING BY INSTITUTIONS
IGXT.OB - Stock Quote for Intelgenx Technologies Corp - IGXT.OB Stock price - real time stock quote for Intelgenx Technologies Corp...
Burn-rate only 300K per Q / IGXT has 3.3 M cash / Do the Math !
http://images.investorshub.advfn.com/ima...
PARTNERDEAL THIS MONTH
http://images.investorshub.advfn.com/ima...
Sales Potential for approved drug CPI-300
http://images.investorshub.advfn.com/ima...
Profitability and 2 new NDA filings in 2012
http://images.investorshub.advfn.com/ima...
MONSTER PIPELINE including a Blockbuster
http://images.investorshub.advfn.com/ima...
Biomedreport Article from Nov 2011
http://www.biomedreports.com/20111111833...
DD------
THIS UNKNOWN GEM IS THE CHEAPEST STOCK WITH THE HIGHEST UPSIDE POTENTIAL IN THE COMPLETE BIOTECH SECTOR .DO YOUR OWN DD AND REALIZE THE MEGA MONSTER POTENTIAL ! GLTA
This Goldmine has a VERY LOW burn-rate of only $1.2 M a year means we have enuff cash untill 2014 EXCLUDING cpi-300 revenue and EXCLUDING upfront payments from upcoming partnerships BUT MORE IMPORTANT TO KNOW IS THAT WE WILL REACH PROFITABILITY THIS YEAR !!!
2x NDA filings for Migraine and Antipsychotic drugs this year which have much bigger market potential than current approved drug .
IGXT has NO DEBT and the Market cap of only 32 M is more than RIDICULOUS for this GOLDMINE .
Intelgenx (IGXT.OB)
Market Cap : $ 32 M
Cash: $ 3.3 M
Price : 0.68 $
NO DEBT
Shares Out : 45 M ( 23 M shares are held by Insiders + Institutions)
HEAVY BUYING BY INSTITUTIONS
IGXT.OB - Stock Quote for Intelgenx Technologies Corp - IGXT.OB Stock price - real time stock quote for Intelgenx Technologies Corp...
Burn-rate only 300K per Q / IGXT has 3.3 M cash / Do the Math !
http://images.investorshub.advfn.com/ima...
PARTNERDEAL THIS MONTH
http://images.investorshub.advfn.com/ima...
Sales Potential for approved drug CPI-300
http://images.investorshub.advfn.com/ima...
Profitability and 2 new NDA filings in 2012
http://images.investorshub.advfn.com/ima...
MONSTER PIPELINE including a Blockbuster
http://images.investorshub.advfn.com/ima...
Biomedreport Article from Nov 2011
http://www.biomedreports.com/20111111833...
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
IntelGenx Announces License Agreement for the Commercialization of CPI-300 in the United States
today announced that it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC ("Edgemont") for the commercialization of IntelGenx' lead product CPI-300 in the United States (U.S.).
Under the terms of the agreement, Edgemont has obtained certain exclusive rights to market and sell CPI-300 in the U.S. In exchange, IntelGenx will receive a $1.0 million upfront payment and launch related milestones totalling up to $4.0 million and will be eligible for additional milestones upon achieving certain sales and exclusivity targets of up to a further $23.5 million. IntelGenx will also receive tiered double-digit royalties on the net sales of CPI-300.
"We are very pleased that Edgemont, a company focused on neurosciences, will be marketing our lead product. A new private company with experienced marketing executives in the psychiatry and neurology space, we strongly believe that Edgemont will be able to devote their time and expertise to ensure that this product will have a successful launch. We are confident that Edgemont it is the ideal company to realize the full potential of CPI-300 and establish it as a successful new brand in the U.S.," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "This partnership will generate increased cash for IntelGenx to invest in its pipeline, thereby accelerating the pace of project development and enhancing shareholder value."
"We are extremely pleased to have been selected as the company to launch CPI-300 in the U.S., and we are fully committed to its success," stated Doug Saltel, President and CEO of Edgemont Pharmaceuticals, LLC. "CPI-300 represents an outstanding strategic fit for us given our focus and expertise in the field of psychiatry, but more importantly, we are excited to be able to launch a product with such a clear and important clinical benefit."
About CPI-300:
CPI-300 is a novel, high mg strength formulation of bupropion HCl, the active ingredient in Wellbutrin XL(R). When launched, CPI-300 will provide high dose bupropion XL patients the opportunity to achieve their mg dose in a single pill versus the multiple pills they currently need to take. Reducing the number of pills per dose is a well-published and important clinical benefit.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at IntelGenX.
About Edgemont Pharmaceuticals:
Edgemont Pharmaceuticals, LLC is a privately held pharmaceutical company with a primary focus and expertise in the field of neuroscience. Edgemont is committed to the development of novel drug formulations and new therapies that can improve patient care. More information is available about the company at Edgemont Pharmaceuticals.
today announced that it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC ("Edgemont") for the commercialization of IntelGenx' lead product CPI-300 in the United States (U.S.).
Under the terms of the agreement, Edgemont has obtained certain exclusive rights to market and sell CPI-300 in the U.S. In exchange, IntelGenx will receive a $1.0 million upfront payment and launch related milestones totalling up to $4.0 million and will be eligible for additional milestones upon achieving certain sales and exclusivity targets of up to a further $23.5 million. IntelGenx will also receive tiered double-digit royalties on the net sales of CPI-300.
"We are very pleased that Edgemont, a company focused on neurosciences, will be marketing our lead product. A new private company with experienced marketing executives in the psychiatry and neurology space, we strongly believe that Edgemont will be able to devote their time and expertise to ensure that this product will have a successful launch. We are confident that Edgemont it is the ideal company to realize the full potential of CPI-300 and establish it as a successful new brand in the U.S.," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "This partnership will generate increased cash for IntelGenx to invest in its pipeline, thereby accelerating the pace of project development and enhancing shareholder value."
"We are extremely pleased to have been selected as the company to launch CPI-300 in the U.S., and we are fully committed to its success," stated Doug Saltel, President and CEO of Edgemont Pharmaceuticals, LLC. "CPI-300 represents an outstanding strategic fit for us given our focus and expertise in the field of psychiatry, but more importantly, we are excited to be able to launch a product with such a clear and important clinical benefit."
About CPI-300:
CPI-300 is a novel, high mg strength formulation of bupropion HCl, the active ingredient in Wellbutrin XL(R). When launched, CPI-300 will provide high dose bupropion XL patients the opportunity to achieve their mg dose in a single pill versus the multiple pills they currently need to take. Reducing the number of pills per dose is a well-published and important clinical benefit.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at IntelGenX.
About Edgemont Pharmaceuticals:
Edgemont Pharmaceuticals, LLC is a privately held pharmaceutical company with a primary focus and expertise in the field of neuroscience. Edgemont is committed to the development of novel drug formulations and new therapies that can improve patient care. More information is available about the company at Edgemont Pharmaceuticals.
rio tinto
Utente Registrato
- Registrato
- 1/11/09
- Messaggi
- 733
- Punti reazioni
- 31
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
yes...è il momento buono!
se hai un po di pazienza
qualche soldo lo porti a casa
$$$$$$$$
Forvivo è già disponibile
Forfivo XL
Il medicinale è disponibile nel mercato, l'accordo per la commercializzazione è fatto e ora .............
Forfivo XL
Il medicinale è disponibile nel mercato, l'accordo per la commercializzazione è fatto e ora .............
Allegati
IntelGenx Reports 2011 Annual Results and Provides Operational Update - MarketWatch
Annunciando i risultati, Dr. Horst G. Zerbe, Presidente e CEO di IntelGenx ha dichiarato: "Siamo estremamente lieti di aver concluso il 2011 con il nostro stato patrimoniale più forte in assoluto, con $ 3,5 milioni in contanti in banca, e nessun debito. Abbiamo inoltre rafforzato la nostra posizione di cassa nel primo trimestre del 2012 attraverso la ricevuta della tassa di firma per l'accordo di licenza con Pharmaceuticals Edgemont per CPI-300, e ci aspettiamo che la commercializzazione di CPI-300 durante l'estate del 2012 sarà migliorare i nostri flussi di cassa ancora ulteriormente.
Annunciando i risultati, Dr. Horst G. Zerbe, Presidente e CEO di IntelGenx ha dichiarato: "Siamo estremamente lieti di aver concluso il 2011 con il nostro stato patrimoniale più forte in assoluto, con $ 3,5 milioni in contanti in banca, e nessun debito. Abbiamo inoltre rafforzato la nostra posizione di cassa nel primo trimestre del 2012 attraverso la ricevuta della tassa di firma per l'accordo di licenza con Pharmaceuticals Edgemont per CPI-300, e ci aspettiamo che la commercializzazione di CPI-300 durante l'estate del 2012 sarà migliorare i nostri flussi di cassa ancora ulteriormente.
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
Thread IGXT has now cash till mid 2015 EXCLUDING | Yahoo! Message Boards - IntelGenx Technologies Corp. | BoardReader
Stanno facendo anche un buon lavoro ma la quotazione sta lentamente scendendo
Ciao playars, speriamo veramente che si trasformi in una pepità d'oro e poi grazie a questa azione ho conosciuto Axelvento
Stanno facendo anche un buon lavoro ma la quotazione sta lentamente scendendo
Ciao playars, speriamo veramente che si trasformi in una pepità d'oro e poi grazie a questa azione ho conosciuto Axelvento
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419